Compugen (CGEN) Competitors $2.27 +0.02 (+0.89%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CGEN vs. BCAX, PRTA, DNTH, CRMD, QURE, ETNB, CGEM, LENZ, PHAR, and ABUSShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Bicara Therapeutics (BCAX), Prothena (PRTA), Dianthus Therapeutics (DNTH), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Pharming Group (PHAR), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Bicara Therapeutics Prothena Dianthus Therapeutics CorMedix uniQure 89bio Cullinan Therapeutics LENZ Therapeutics Pharming Group Arbutus Biopharma Compugen (NASDAQ:CGEN) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking. Does the media favor CGEN or BCAX? In the previous week, Bicara Therapeutics had 4 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Bicara Therapeutics and 1 mentions for Compugen. Compugen's average media sentiment score of 0.32 beat Bicara Therapeutics' score of 0.15 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in CGEN or BCAX? 12.2% of Compugen shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer CGEN or BCAX? Compugen presently has a consensus target price of $4.00, indicating a potential upside of 84.76%. Bicara Therapeutics has a consensus target price of $43.00, indicating a potential upside of 259.38%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has higher earnings and valuation, CGEN or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than Compugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$33.46M5.77-$18.75M$0.02108.25Bicara TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community believe in CGEN or BCAX? Compugen received 302 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 64.38% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30964.38% Underperform Votes17135.63% Bicara TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Is CGEN or BCAX more profitable? Compugen has a net margin of 2.67% compared to Bicara Therapeutics' net margin of 0.00%. Compugen's return on equity of 2.62% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% Bicara Therapeutics N/A N/A N/A SummaryCompugen beats Bicara Therapeutics on 8 of the 14 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.21M$2.99B$5.37B$9.10BDividend YieldN/A1.89%5.37%4.00%P/E Ratio108.2545.2087.4217.48Price / Sales5.77289.281,281.3978.80Price / CashN/A189.5236.6032.90Price / Book2.973.964.934.65Net Income-$18.75M-$40.99M$117.96M$224.76M7 Day Performance8.25%2.61%2.21%2.97%1 Month Performance41.50%0.04%3.20%4.97%1 Year Performance11.60%-1.03%26.67%21.85% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.2679 of 5 stars$2.27+0.9%$4.00+76.2%+16.0%$202.58M$33.46M113.5070Gap UpBCAXBicara TherapeuticsN/A$12.99-9.7%$43.00+231.0%N/A$706.86MN/A0.0032News CoveragePRTAProthena2.4155 of 5 stars$13.13+0.6%$46.50+254.2%-58.3%$706.51M$133.35M-5.29130Positive NewsDNTHDianthus Therapeutics1.9014 of 5 stars$23.04-4.8%$46.43+101.5%+67.4%$681.92M$5.37M-9.2280Short Interest ↑CRMDCorMedix2.4423 of 5 stars$11.12-0.6%$15.67+40.9%+273.3%$674.73M$12.26M-13.7330QUREuniQure4.0399 of 5 stars$13.79-0.4%$33.88+145.6%+153.2%$672.17M$28.59M-2.78500Analyst ForecastPositive NewsETNB89bio2.207 of 5 stars$6.31-3.1%$30.33+380.7%-42.8%$669.66MN/A-2.1740Analyst ForecastShort Interest ↑News CoverageCGEMCullinan Therapeutics2.0397 of 5 stars$11.04-1.3%$31.67+186.8%-10.9%$642.84M$18.94M-3.8930LENZLENZ Therapeutics2.2055 of 5 stars$23.200.0%$35.40+52.6%N/A$638.02MN/A0.00110Short Interest ↑Positive NewsPHARPharming Group2.5937 of 5 stars$9.37-3.5%$27.00+188.2%-17.5%$635.61M$285.75M-36.04280News CoverageABUSArbutus Biopharma2.8146 of 5 stars$3.35+1.8%$5.50+64.2%+35.6%$634.80M$6.74M-7.7973Analyst ForecastNews Coverage Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Prothena Alternatives Dianthus Therapeutics Alternatives CorMedix Alternatives uniQure Alternatives 89bio Alternatives Cullinan Therapeutics Alternatives LENZ Therapeutics Alternatives Pharming Group Alternatives Arbutus Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGEN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts